The role of direct oral anticoagulants in the era of COVID-19: are antiviral therapy and pharmacogenetics limiting factors?
Croat Med J
; 63(3): 287-294, 2022 Jun 22.
Статья
в английский
| MEDLINE | ID: covidwho-1898169
ABSTRACT
In patients with COVID-19, thromboinflammation is one of the main causes of morbidity and mortality, which makes anticoagulation an integral part of treatment. However, pharmacodynamic and pharmacokinetic properties of direct oral anticoagulants (DOACs) limit the use of this class of anticoagulants in COVID-19 patients due to a significant interference with antiviral agents. DOACs use in COVID-19 hospitalized patients is currently not recommended. Furthermore, patients already on oral anticoagulant drugs should be switched to heparin at hospital admission. Nevertheless, outpatients with a confirmed diagnosis of COVID-19 are recommended to continue prior DOAC therapy. More studies are required to clarify the pathogenesis of COVID-19-induced derangement of the coagulation system in order to recommend an appropriate anticoagulant treatment.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Thrombosis
/
COVID-19 Drug Treatment
Пределы темы:
Люди
Язык:
английский
Журнал:
Croat Med J
Тематика журнала:
Медицина
Год:
2022
Тип:
Статья
Документы, близкие по теме
MEDLINE
...
LILACS
LIS